- Ozairi EA, Taghadom E, Irshad M, Yousef AA, AlKandari J, Al-Najim W, Alabdulkader S, Miras AD, le Roux CW. Combining glucagon-like peptide 1 analogues with sodium-glucose cotransporter 2 inhibitors to treat patients with type 1 diabetes, BMI > 25 kg/m(2), and chronic kidney disease – A randomised, controlled pilot study Diabetes Res Clin Pract
-
Davey MG, Donlon NE, Clerkin M, Bolger JC, Robb WB.
Minimally Invasive Hypoabsorptive Bariatric Surgery – A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials Obes Surg
-
Dubois L, Bédard B, Goulet D, Prud'homme D, Tremblay RE, Boivin M.
Food patterns and body weight in young adulthood and associations with food consumption throughout childhood: findings from a birth-cohort study Br J Nutr
- Keely SJ, Barrett KE. The role of the gut in obesity – new insights into the physiology of therapeutic approaches J Physiol
-
Brennan DJ, Lynch L.
Will GLP-1 Agonists Weaken the Links between Obesity and Cancer? Cancer Discov
-
le Roux CW, Wharton S, Bozkurt B, Platz E, Bleckert G, Ajaz Hussain S, Brueckmann M, Startseva E, Kloer IM, Kaplan LM.
Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1) Diabetes Obes Metab
-
Chumakova M, Finucane FM, Chen YJ, Juo YY.
Impact of the 2025 Lancet Diagnostic Criteria on Obesity Treatment in the United States Clin Obes
-
Wharton S, le Roux CW, Bozkurt B, Platz E, Bleckert G, Ajaz Hussain S, Brueckmann M, Startseva E, Kloer IM, Kaplan LM.
Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes Diabetes Obes Metab
-
Donovan CM, Buffini M, Walton J, Kehoe L, Kearney J, Flynn A, Nugent A, McNulty B.
Trends in the weight status of adults in Ireland between 1990 and 2024 Eur J Nutr
-
Purnell JQ, Le Roux CW.
Metabolic and appetitive regulation of adipocyte mass during treatment of obesity J Intern Med